The latest price target for Corvus Pharma (NASDAQ:CRVS) was reported by Oppenheimer on November 13, 2024. The analyst firm set a price target for $14.00 expecting CRVS to rise to within 12 months (a possible 179.44% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Corvus Pharma (NASDAQ:CRVS) was provided by Oppenheimer, and Corvus Pharma reiterated their outperform rating.

There is no last upgrade for Corvus Pharma

There is no last downgrade for Corvus Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a reiterated with a price target of $8.00 to $14.00. The current price Corvus Pharma (CRVS) is trading at is $5.01, which is out of the analyst’s predicted range.